SEC Form 4 · accession 0001179110-18-012610
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jared Watkin
Officer — Senior Vice President
Period of report
Nov 2, 2018
Accepted (ET)
Nov 6, 2018 · 5:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000001800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common shares without par value | Nov 2, 2018 | M | 65,000 | $38.40 | A | 128,640 | D | |
| Common shares without par value | Nov 2, 2018 | S | 65,000 | $71.00 | D | 63,640 | D | |
| Common shares without par valueF1 | holding | — | — | — | 521 | I | Profit Sharing Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F2,F3 | $38.40 | Nov 2, 2018 | M | 65,000 | D | — | Feb 18, 2026 | Common shares | 65,000 | 109,657 | D |
Explanation of responses
- F1Balance in the Abbott Laboratories Stock Retirement Trust as of November 2, 2018.
- F2Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
- F3Options for these shares became exercisable on 02/19/2017 and 02/19/2018.
Remarks
These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).